{"groups":[{"description":"Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"FG000","title":"Panobinostat + Bortezomib"},{"description":"Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"FG001","title":"Placebo + Bortezomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"}],"type":"Abnormal test proceedure results"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Administrative problems"},{"reasons":[{"groupId":"FG000","numSubjects":"130"},{"groupId":"FG001","numSubjects":"66"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"17"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"153"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}],"type":"New Cancer therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}],"type":"Untreated"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"18"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"387"},{"groupId":"FG001","numSubjects":"381"}],"type":"STARTED"},{"achievements":[{"comment":"completed all planned cycles of study treatment as per protocol","groupId":"FG000","numSubjects":"102"},{"comment":"completed all planned cycles of study treatment as per protocol","groupId":"FG001","numSubjects":"102"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"285"},{"groupId":"FG001","numSubjects":"279"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}